Aims and scope
Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings.
Experimental Hematology & Oncology publishes original work, hypothesis, commentaries and timely reviews. With open access and rapid turnaround time from submission to publication, the journal strives to be a hub for disseminating new knowledge and discussing controversial topics for both basic scientists and busy clinicians in the closely related fields of hematology and oncology.
All articles published by Experimental Hematology & Oncology are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
As authors of articles published in Experimental Hematology & Oncology you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BioMed Central license agreement.
For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. Experimental Hematology & Oncology therefore levies an article-processing charge of £1495/$2580/€2105 for each article accepted for publication. If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
BioMed Central provides a free open access funding support service to help authors discover and apply for article processing charge funding. Visit our OA funding and policy support page to view our list of research funders and institutions that provide funding for APCs, and to learn more about our email support service.
All articles published in Experimental Hematology & Oncology are included in:
- PubMed Central
The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.
We are working closely with relevant indexing services including Web of Science (Thomson Reuters) to ensure that articles published in Experimental Hematology & Oncology will be available in their databases when appropriate.
Experimental Hematology & Oncology operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous.
The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.
Submitted manuscripts will generally be reviewed by two or more experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the manuscript is sufficiently clear for publication. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board.
Edited by Delong Liu and Zihai Li, Experimental Hematology & Oncology is supported by an expert Editorial Board.
All manuscripts submitted to Experimental Hematology & Oncology should adhere to BioMed Central's editorial policies.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Appeals and complaints
If you wish to appeal a rejection or make a complaint you should, in the first instance, contact the Editor who will provide details of the journal's complaints procedure. For complaints that cannot be resolved with the Editor, the authors should contact the Publisher.
Citing articles in Experimental Hematology & Oncology
Articles in Experimental Hematology & Oncology should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Exp Hematol Oncol [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Exp Hematol Oncol 2009, 1:115.
refers to article 115 from Volume 1 of the journal.
Why publish your article in Experimental Hematology & Oncology
Experimental Hematology & Oncology's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.
Speed of publication
Experimental Hematology & Oncology offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.
Online publication in Experimental Hematology & Oncology gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Experimental Hematology & Oncology are included in article alerts and regular email updates. Some may be highlighted on Experimental Hematology & Oncology’s pages and on the BioMed Central homepage.
In addition, articles published in Experimental Hematology & Oncology may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Experimental Hematology & Oncology. A list of articles recently press-released by journals published by BioMed Central is available here.
As an author of an article published in Experimental Hematology & Oncology you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BioMed Central license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.